Brilinta significantly reduced rate of composite of stroke and death in THALES trial

This article was originally published here

This was a statistically significant and clinically meaningful reduction. Furthermore, aspirin plus Brilinta significantly reduced the rate of the first secondary endpoint of ischaemic stroke by 21%, compared

The post Brilinta significantly reduced rate of composite of stroke and death in THALES trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply